ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children's Oncology Group Study.

Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar HA, Scull B, Karri V, Tanna J, Hanley PJ, Hermiston ML, Allen CE, Bollard CM